Japanese Journal of Cancer and Chemotherapy最新文献

[A Case of Rectal Cancer Where the Intestinal Separation Line Was Significantly Altered by the Implementation of Intraoperative ICG Fluorescence Imaging]. [术中应用ICG荧光显像改变肠分隔线的直肠癌1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Yuki Takano, Masatoshi Shigoka, Eiji Hidaka, Satoshi Tabuchi, Naokazu Chiba, Tetsuo Ishizaki, Yuichi Nagakawa, Shigeyuki Kawachi

引用次数: 0

[Successful Hemostasis with Chemoradiotherapy for Unresectable Large HER2-Positive Advanced Gastric Cancer with Massive Bleeding-A Case Report]. 放化疗成功止血治疗晚期不可切除大her2阳性胃癌大出血1例

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Hiroaki Miyake, Yuki Fujii, Ayumi Yokoyama, Kota Tanuma, Tomohide Adachi, Shigemichi Hirose, Shinsuke Funakoshi

{"title":"[Successful Hemostasis with Chemoradiotherapy for Unresectable Large HER2-Positive Advanced Gastric Cancer with Massive Bleeding-A Case Report].","authors":"Hiroaki Miyake, Yuki Fujii, Ayumi Yokoyama, Kota Tanuma, Tomohide Adachi, Shigemichi Hirose, Shinsuke Funakoshi","doi":"","DOIUrl":"","url":null,"abstract":"In this case report, we explored the effectiveness of chemoradiotherapy(CRT)for an unresectable large HER2-positive advanced gastric cancer in a 67-year-old male patient. The patient presented with upper abdominal distension and severe anemia. Contrast-enhanced CT scan revealed a 13 cm large tumor in the stomach, with multiple metastases to the liver and lungs. The patient was treated with CRT, combining radiotherapy with FOLFOX chemotherapy to manage persistent massive bleeding. Bleeding was successfully controlled within approximately 2 weeks, eliminating the need for further transfusions and allowing the patient to resume oral intake. Following CRT, trastuzumab-based chemotherapy resulted in significant tumor shrinkage, enabling continued treatment. This case highlights the potential of CRT as an effective treatment option for unresectable HER2-positive advanced gastric cancer complicated by massive bleeding. The successful control of bleeding using CRT might improve both the prognosis and quality of life(QOL)for such patients. We present this case to highlight the therapeutic benefits of CRT in similar clinical scenarios.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"463-466"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[MRD Testing in Lung Cancer-Latest Insights and Developments]. [MRD检测在肺癌中的最新见解和发展]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Takahiro Karasaki, Hidehito Horinouchi

{"title":"[MRD Testing in Lung Cancer-Latest Insights and Developments].","authors":"Takahiro Karasaki, Hidehito Horinouchi","doi":"","DOIUrl":"","url":null,"abstract":"In lung cancer, circulating tumor DNA(ctDNA)analysis has already been clinically implemented, for example, to detect resistance mutations to EGFR-TKIs. Recently, as in many other cancer types, postoperative detection of molecular residual disease (MRD) has been shown to correlate with poor prognosis. This article summarizes the latest findings on MRD research in lung cancer. A literature review as of May 2024 identified 41 studies on lung cancer MRD. Although no randomized trials have yet utilized MRD to guide treatment decisions in this field, retrospective studies consistently demonstrate its utility in predicting recurrence. In Japan, prospective studies such as JCOG2111A(MRDSEEKER trial, NCT06854939), which evaluates the kinetics and detection rate of MRD using a tumor-informed personalized assay, are currently underway. Notably, recent subset analyses of ctDNA/MRD assessments before and after treatment in randomized trials on perioperative chemoimmunotherapy and adjuvant therapy have garnered significant attention. However, the sensitivity of the assays used in these studies possibly remains suboptimal for lung cancer. Future prospective trials incorporating more sensitive, second-generation assays may be warranted.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"443-447"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Current Status of Molecular Residual Disease Testing in Genitourinary Cancers]. [泌尿生殖系统肿瘤分子残留病检测现状]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Taigo Kato

引用次数: 0

[Overview of Current Status of Clinical Development by Molecular Residual Disease(MRD)]. [分子残留病（MRD）的临床发展现状综述]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Shin Kobayashi, Yoshiaki Nakamura

引用次数: 0

[A Case of a Patient with Lung Adenocarcinoma on Hemodialysis Treated with Atezolizumab+Carboplatin+Nab-Paclitaxel]. [阿特唑单抗+卡铂+ nab -紫杉醇治疗血液透析肺腺癌1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Junichi Hanaka, Mariko Kasuga, Yoshitaka Sakamoto, Mizuki Hagiya, Jun Nakauchi, Takahito Komiyama, Yugo Fukamizu, Takanori Ohata

{"title":"[A Case of a Patient with Lung Adenocarcinoma on Hemodialysis Treated with Atezolizumab+Carboplatin+Nab-Paclitaxel].","authors":"Junichi Hanaka, Mariko Kasuga, Yoshitaka Sakamoto, Mizuki Hagiya, Jun Nakauchi, Takahito Komiyama, Yugo Fukamizu, Takanori Ohata","doi":"","DOIUrl":"","url":null,"abstract":"A 70-year-old man presented with anorexia and cough, and CT showed an infiltrative shadow in the right upper lobe. Bronchoscopy revealed unresectable advanced lung carcinoma(cT4N2M1a, cStage ⅣA). The patient had chronic renal failure due to type 2 diabetes mellitus and had been undergoing hemodialysis for 6 years. Four courses of primary chemotherapy( atezolizumab+carboplatin[CBDCA]+nab-paclitaxel[nab-PTX][atezolizumab 1,200 mg/body weight, CBDCA target AUC=5, nab-PTX 100 mg/m2 every 3 weeks])were administered. Thereafter, 3 courses of maintenance treatment with atezolizumab alone(1,200 mg/body weight every 3 weeks)were administered. At this point, the primary tumor was enlarged, and the patient was diagnosed with progressive disease(PD). After 4 courses of second-line chemotherapy with docetaxel(DTX)+ramucirumab(RAM)(DTX 60 mg/m2 day 1, RAM 8 mg/kg day 1, 15, every 4 weeks), the primary tumor temporarily shrank but then re-expanded; therefore, the patient remained in a state of PD. The general condition deteriorated, and he was referred to the palliative care department where he died peacefully.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"475-477"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Locally Advanced Appendiceal Cancer Successfully Resected after Treatment with mFOLFOX6 plus Bevacizumab]. [mFOLFOX6联合贝伐单抗治疗局部晚期阑尾癌成功切除1例]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Nobuhisa Tanioka, Michio Kuwahara, Takashi Sakai, Yujiro Bunno, Shigeto Shimizu, Toyokazu Akimori

{"title":"[A Case of Locally Advanced Appendiceal Cancer Successfully Resected after Treatment with mFOLFOX6 plus Bevacizumab].","authors":"Nobuhisa Tanioka, Michio Kuwahara, Takashi Sakai, Yujiro Bunno, Shigeto Shimizu, Toyokazu Akimori","doi":"","DOIUrl":"","url":null,"abstract":"An 80-year-old woman presented with lower abdominal distension for the past 3 days. Abdominal contrast-enhanced CT revealed an irregularly shaped mass measuring 80×50 mm in the right lower abdomen, with a contrast effect. The final diagnosis was locally advanced appendiceal cancer with multiple invasions into the adjacent ileum and retroperitoneum. After 7 courses of preoperative chemotherapy with mFOLFOX6 plus bevacizumab, the tumor reduced in size, and laparoscopic ileocecal resection with D3 lymph node dissection was performed 4 months after diagnosis. Histopathological examination revealed appendiceal cancer, tub1-tub2, ypT4aN0M0, pStage ⅡB, with a histological Grade of 2 and a curative degree of A. The patient had no signs of recurrence 2 years and 6 months after surgery without receiving adjuvant chemotherapy. We reported a case of locally advanced appendiceal cancer that was successfully treated with mFOLFOX6 plus bevacizumab as preoperative chemotherapy and was curatively resected without combined resection of surrounding organs, with a discussion of the relevant literature.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"467-469"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[A Case of Double Cancers of the Gallbladder and Duodenal Papilla]. 胆囊癌、十二指肠乳头癌1例

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Kota Yamamoto, Takahiro Ishimori, Taiki Okada, Takeshi Sasaki, Yumi Mikajiri, Takahiro Terashima, Shunji Kawamoto

引用次数: 0

[Current Status of ctDNA-Based MRD Testing in Breast Cancer]. [基于ctdna的乳腺癌MRD检测现状]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Yukinori Ozaki, Hiroji Iwata

引用次数: 0

[Operational Construction and Effectiveness Verification of an HBV Reactivation Management Protocol for Cancer Chemotherapy Patients Based on Medical Information System Safety Management]. [基于医疗信息系统安全管理的肿瘤化疗患者HBV再激活管理方案的操作构建及有效性验证]。

Japanese Journal of Cancer and Chemotherapy Pub Date : 2025-06-01

Masato Komuro, Yuri Toda, Sae Ishikawa, Hiroshi Hyakutake, Tomofumi Watanabe, Yumiko Shimanuki, Maho Tanaka, Komei Shimokawa, Takahiro Nishimura, Kengo Miyo

{"title":"[Operational Construction and Effectiveness Verification of an HBV Reactivation Management Protocol for Cancer Chemotherapy Patients Based on Medical Information System Safety Management].","authors":"Masato Komuro, Yuri Toda, Sae Ishikawa, Hiroshi Hyakutake, Tomofumi Watanabe, Yumiko Shimanuki, Maho Tanaka, Komei Shimokawa, Takahiro Nishimura, Kengo Miyo","doi":"","DOIUrl":"","url":null,"abstract":"Hepatitis B virus(HBV)reactivation during cancer chemotherapy is a life-threatening condition with a high risk of severe or fulminant disease. Effective management is essential; however, individual physicians may lack a structured system for handling HBV-related risks, and both physicians and pharmacists often face significant administrative burdens, including making inquiries, entering orders for additional testing, and verifying appropriate orders. To address this challenge, we developed a pharmacist-initiated, protocol-based pharmacotherapy management system for HBV(PBPM-HBV), allowing pharmacists to order HBV-related tests on behalf of physicians in accordance with the Guidelines for the Safety Management of Medical Information Systems. Implementing PBPM-HBV under these guidelines reduced the number of HBV-related test requests from 224 to 50, resulting in an approximately 75.7% reduction in workload. The introduction of PBPM-HBV at our hospital has improved workflow efficiency for both physicians and pharmacists while ensuring the safety of the medical information system and cancer chemotherapy processes.","PeriodicalId":35588,"journal":{"name":"Japanese Journal of Cancer and Chemotherapy","volume":"52 6","pages":"457-461"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144498235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0